ClinicalTrials.gg
RecruitingNCT05599139IULIDUpdated Feb 6, 2026

Iodine Uptake After a Low Iodine Diet

An interventional study of Low iodine diet in Differentiated Thyroid Cancer, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Thyroid Neoplasms with a site in Netherlands — 6 open to participants now, 8 under way, 1 of them phase 3. Thyroid Neoplasms · Netherlands.

Planned enrollment
18th of 24
25 · median 76
Started
2023
the only one that year
No phase
6 of 28
2 open now
Registered
24th of 28
by date
Lead sponsor
5 of 28
University Medical Center Groningen

Among the 28 studies in Thyroid Neoplasms with a site in Netherlands, this one is the 18th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2023, is one of 6 with no phase, and was the 24th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

6 of the 28 studies in Thyroid Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Thyroid Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the difference in thyroid uptake of a low dose radioactive iodine (10 MBq 123-I or 37 MBq 123-I) in athyreotic patients with differentiated thyroid carcinoma before and after a low iodine diet (LID) of 7 days.

The main question it aims to answer is:

  • What is the difference in iodine uptake before and after a LID of 7 days?

Uptake of a low dose of 123-iodine will be measured in participants before and after a low iodine diet of 7 days. Researchers will compare the uptake (%) before and after the LID.

Read the detailed description

Rationale:

Differentiated thyroid carcinoma (DTC) is the most common form of thyroid cancer. The initial treatment of DTC consists of a total thyroidectomy followed by ablation therapy with radioactive iodine (131I) which destroy residual thyroid (cancer) tissue. Before starting the (ablation) therapy with 131I, patients have to follow a low iodine diet (LID) reducing the iodine intake \< 50 mcg per day. Depleting the overall iodine store in the body theoretically maximizes the expression of the sodium-iodine symporter (NIS). This increased NIS expression results in an increase of the uptake of 131I in remaining thyroid (cancer) cells during 131I therapy and therefore improves the ablation success rates. However, there is no prospective data to support this, merely some retrospective contradictionary data. Patients experience the strict adherence to LID as stressful, distasteful and overwhelming in combination with a new diagnosis of cancer and withdrawal from thyroid hormone. Besides, they are afraid to apply the LID inadequately, which complicates achieving a balanced diet, essential in cancer recovery.

Objective:

To compare the difference in thyroid uptake of a low dose radioactive iodine (10 MBq 123I or 37 MBq 123I), in DTC patients after thyroidectomy, before and after a LID of 7 days.

Study design: observational, single center study performed in the University Medical Center Groningen (UMCG) Groningen, the Netherlands.

Study population: Patients, men and women above the age of 18 years, with a histopathological confirmed diagnosis of DTC who will receive 131I ablation therapy and have to follow a LID according to the Dutch DTC guideline.

Main study parameters/endpoints: The primary endpoint is the clinical relevant difference of a twofold uptake increase, in the thyroid remnant after thyroidectomy in DTC patients, a 10 MBq 123I or 37 MBq 123I tracer dose before and after a LID of 7 days.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

  • Burden: Low risk patients (according to the Dutch DTC guideline) will receive 10 MBq 123I twice, followed by a thyroid uptake measurement and will have to collect their urine for 24 hours twice. High risk patients (according to the Dutch DTC guideline) will receive 10 MBq 123I once, followed by a thyroid uptake measurement and have to collect their urine for 24 hours twice. On the day of the first administration of 10 MBq 123I, 1 blood sample (5 ml) will be collected. Low risk patients have to make three additional site visits to the UMCG, high risk patients two additional site visits.
  • Risks: The administration of two times 10 MBq will lead to an extra radiation exposure of 0,76 mSv for low risk patients and 0,38 mSv for high risk patients. Blood sampling carriers a negligible risk of a hematoma. The 24 hours urine collection is without additional risk for the patient or the lab technician.

The note of the daily food intake is without additional risk for the patient.

- Benefits: None, participants will participate based on altruistic motives.

03

Conditions studied

  • Differentiated Thyroid Cancer

Browse trials for

Keywords

  • Low iodine diet
  • Iodine uptake
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients, men and women above the age of 18 years, have to be diagnosed with DTC and have to follow a LID prior to the 131I ablation therapy according to the Dutch DTC guideline
  • Patients have to be fit to adhere to the study protocol
  • Patients have to be able to read and understand the Dutch language

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Patients using amiodarone
  • Patients receiving iodinated contrast \< 3 months before the LID
  • Pregnancy
  • Patients prepared for ablation therapy with rhTSH
  • Renal impairment, EGFR \<30ml/min/1,73m2
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Other
    Low iodine diet

    Patients recieve a low iodine diet. Consecutive iodine uptake measurements will be made before and after starting this low iodine diet. This study is constructed of only one study arm, and patients will be compared to themselves.

    Behavioral: Low iodine diet

Interventions

  • BehavioralLow iodine diet

    Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake \< 50 mcg per day and thereby depleting the overall iodine store in the body.

06

What researchers measure

Primary outcomes

  1. Iodine uptake

    Difference in iodine uptake in percentage

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The IPD will not be available to other researchers as this is not included in the patient consent.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Mar 2026, 37 months after the start.

Of 126 non-industry interventional studies with no phase under Thyroid Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 78. This study's planned 37 months is below that.

Counting every sponsor, half of 127 studies reached it within 46 months; a quarter within 14 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2022
First posted
Oct 31, 2022
StartActual
Feb 22, 2023
Primary completionEst.
Mar 30, 2026
CompletionEst.
Aug 31, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05599139
Responsible party
Sponsor
First posted
Oct 31, 2022
Start date
Feb 22, 2023
Primary completion
Mar 30, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

Wouter Zandee, Dr.
Contact
w.t.zandee@umcg.nl
+31503613731
Mirthe Links, BSc.
Contact
m.h.links@umcg.nl
+31503610973
Wouter Zandee, Dr.
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion